利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

127 条记录 (耗时 0.021 秒)

    System and method for monitoring diastolic function using an implantable medical device
    1.
    发明授权
    System and method for monitoring diastolic function using an implantable medical device 有权
    使用可植入医疗装置监测舒张功能的系统和方法

    公开(公告)号：US08280523B2

    公开(公告)日：2012-10-02

    申请号：US12341355

    申请日：2008-12-22

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/36 ,  A61N1/378

    CPC分类号： A61N1/3702 ,  A61N1/3627 ,  A61N1/36507 ,  A61N1/368 ,  A61N1/3712

    摘要： Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.

    摘要翻译： 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中，可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地，T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中，基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。

    System and method for monitoring diastolic function using an implantable medical device
    2.
    发明授权
    System and method for monitoring diastolic function using an implantable medical device 有权
    使用可植入医疗装置监测舒张功能的系统和方法

    公开(公告)号：US08874213B2

    公开(公告)日：2014-10-28

    申请号：US13601569

    申请日：2012-08-31

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/362 ,  A61N1/37 ,  A61N1/368 ,  A61N1/365

    CPC分类号： A61N1/3702 ,  A61N1/3627 ,  A61N1/36507 ,  A61N1/368 ,  A61N1/3712

    摘要： Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.

    摘要翻译： 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中，可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地，T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中，基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。

    SYSTEM AND METHOD FOR MONITORING DIASTOLIC FUNCTION USING AN IMPLANTABLE MEDICAL DEVICE
    3.
    发明申请
    SYSTEM AND METHOD FOR MONITORING DIASTOLIC FUNCTION USING AN IMPLANTABLE MEDICAL DEVICE 有权
    使用可植入医疗装置监测脱脂功能的系统和方法

    公开(公告)号：US20120330371A1

    公开(公告)日：2012-12-27

    申请号：US13601569

    申请日：2012-08-31

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/365

    CPC分类号： A61N1/3702 ,  A61N1/3627 ,  A61N1/36507 ,  A61N1/368 ,  A61N1/3712

    摘要： Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.

    摘要翻译： 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中，可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地，T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中，基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。

    Implantable systems and methods for monitoring BNP levels, HF and MI
    4.
    发明授权
    Implantable systems and methods for monitoring BNP levels, HF and MI 有权
    用于监测BNP水平，HF和MI的植入式系统和方法

    公开(公告)号：US08326422B2

    公开(公告)日：2012-12-04

    申请号：US12341074

    申请日：2008-12-22

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/00

    CPC分类号： A61N1/3627 ,  A61B5/024 ,  A61B5/0452 ,  A61B5/0464 ,  A61B5/053 ,  A61B5/145 ,  A61N1/36557 ,  A61N1/36585 ,  A61N1/37258

    摘要： Methods for monitoring a patient's level of B-type natriuretic peptide (BNP), and implantable cardiac systems capable of performing such methods, are provided. A ventricle is paced for a period of time to provoke a ventricular evoked response, and a ventricular intracardiac electrogram (IEGM) indicative of the ventricular evoked response is obtained. Based on the ventricular IEGM, there is a determination of at least one ventricular evoked response metric (e.g., ventricular evoked response peak-to-peak amplitude, ventricular evoked response area and/or ventricular evoked response maximum slope), and the patient's level of BNP is monitored based on determined ventricular evoked response metric(s). Based on the monitored level's of BNP, the patients heart failure (HF) condition and/or risks and/or occurrences of certain events (e.g., an acute HF exacerbation and/or an acute myocardial infarction) can be monitored.

    摘要翻译： 提供了用于监测患者B型利钠肽（BNP）水平的方法，以及能够执行这些方法的可植入心脏系统。 心室起搏一段时间以引发心室诱发反应，并获得指示心室诱发反应的心室心内电图（IEGM）。 基于心室IEGM，确定至少一个心室诱发反应度量（例如，心室诱发反应峰 - 峰幅度，心室诱发反应面积和/或心室诱发反应最大斜率）和患者的水平 基于确定的心室诱发反应度量监测BNP。 基于监测的BNP水平，可以监测患者的心力衰竭（HF）状况和/或某些事件的风险和/或发生（例如急性HF急性发作和/或急性心肌梗塞）。

    SYSTEM AND METHOD FOR MONITORING DIASTOLIC FUNCTION USING AN IMPLANTABLE MEDICAL DEVICE
    5.
    发明申请
    SYSTEM AND METHOD FOR MONITORING DIASTOLIC FUNCTION USING AN IMPLANTABLE MEDICAL DEVICE 有权
    使用可植入医疗装置监测脱脂功能的系统和方法

    公开(公告)号：US20100161006A1

    公开(公告)日：2010-06-24

    申请号：US12341355

    申请日：2008-12-22

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/36

    CPC分类号： A61N1/3702 ,  A61N1/3627 ,  A61N1/36507 ,  A61N1/368 ,  A61N1/3712

    摘要： Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.

    摘要翻译： 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中，可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地，T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中，基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。

    IMPLANTABLE SYSTEMS AND METHODS FOR MONITORING BNP LEVELS, HF AND MI
    6.
    发明申请
    IMPLANTABLE SYSTEMS AND METHODS FOR MONITORING BNP LEVELS, HF AND MI 有权
    用于监测BNP水平，HF和MI的可植入系统和方法

    公开(公告)号：US20100160993A1

    公开(公告)日：2010-06-24

    申请号：US12341074

    申请日：2008-12-22

    申请人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    发明人： Allen Keel ,  Steve Koh ,  Taraneh Ghaffari Farazi

    IPC分类号： A61N1/365

    CPC分类号： A61N1/3627 ,  A61B5/024 ,  A61B5/0452 ,  A61B5/0464 ,  A61B5/053 ,  A61B5/145 ,  A61N1/36557 ,  A61N1/36585 ,  A61N1/37258

    摘要： Methods for monitoring a patient's level of B-type natriuretic peptide (BNP), and implantable cardiac systems capable of performing such methods, are provided. A ventricle is paced for a period of time to provoke a ventricular evoked response, and a ventricular intracardiac electrogram (IEGM) indicative of the ventricular evoked response is obtained. Based on the ventricular IEGM, there is a determination of at least one ventricular evoked response metric (e.g., ventricular evoked response peak-to-peak amplitude, ventricular evoked response area and/or ventricular evoked response maximum slope), and the patient's level of BNP is monitored based on determined ventricular evoked response metric(s). Based on the monitored level's of BNP, the patients heart failure (HF) condition and/or risks and/or occurrences of certain events (e.g., an acute HF exacerbation and/or an acute myocardial infarction) can be monitored.

    摘要翻译： 提供了用于监测患者B型利钠肽（BNP）水平的方法，以及能够执行这些方法的可植入心脏系统。 心室起搏一段时间以引发心室诱发反应，并获得指示心室诱发反应的心室心内电图（IEGM）。 基于心室IEGM，确定至少一个心室诱发反应度量（例如，心室诱发反应峰 - 峰幅度，心室诱发反应面积和/或心室诱发反应最大斜率）和患者的水平 基于确定的心室诱发反应度量监测BNP。 基于监测的BNP水平，可以监测患者的心力衰竭（HF）状况和/或某些事件的风险和/或发生（例如急性HF急性发作和/或急性心肌梗塞）。

    Systems and methods for optimizing multi-site cardiac pacing and sensing configurations for use with an implantable medical device
    7.
    发明授权
    Systems and methods for optimizing multi-site cardiac pacing and sensing configurations for use with an implantable medical device 有权
    用于优化与可植入医疗装置一起使用的多部位心脏起搏和感测配置的系统和方法

    公开(公告)号：US08209010B2

    公开(公告)日：2012-06-26

    申请号：US12703069

    申请日：2010-02-09

    申请人： Kyungmoo Ryu ,  Stuart Rosenberg ,  Allen Keel ,  Taraneh Ghaffari Farazi ,  Xiaoyi Min

    发明人： Kyungmoo Ryu ,  Stuart Rosenberg ,  Allen Keel ,  Taraneh Ghaffari Farazi ,  Xiaoyi Min

    IPC分类号： A61N1/00

    CPC分类号： A61N1/36514 ,  A61N1/3627 ,  A61N1/368 ,  A61N1/3708

    摘要： Techniques are provided for use with an implantable cardiac stimulation device equipped for multi-site left ventricular (MSLV) pacing using a multi-pole LV lead. In one example, referred to herein as QuickStim, cardiac pacing configurations are optimized based on an assessment of hemodynamic benefit and device longevity. In another example, referred to herein as QuickSense, cardiac sensing configurations are optimized based on sensing profiles input by a clinician. Various virtual sensing channels are also described that provide for the multiplexing or gating of sensed signals. Anisotropic oversampling is also described.

    摘要翻译： 提供技术用于使用多极LV引线配备用于多位点左心室（MSLV）起搏的可植入心脏刺激装置。 在一个例子中，本文称为QuickStim，基于对血液动力学益处和器械寿命的评估来优化心脏起搏配置。 在另一个例子中，本文称为QuickSense，基于由临床医生输入的感测曲线来优化心脏感测配置。 还描述了各种虚拟感测通道，其提供感测信号的复用或门控。 还描述了各向异性过采样。

    System and Method for ATP Treatment Utilizing Multi-Electrode Left Ventricular Lead
    8.
    发明申请
    System and Method for ATP Treatment Utilizing Multi-Electrode Left Ventricular Lead 审中-公开
    使用多电极左心室铅的ATP治疗的系统和方法

    公开(公告)号：US20120191154A1

    公开(公告)日：2012-07-26

    申请号：US13012574

    申请日：2011-01-24

    申请人： Kyungmoo Ryu ,  Stuart Rosenberg ,  Allen Keel ,  Taraneh Ghaffari Farazi ,  Richard Williamson ,  Mark Carlson

    发明人： Kyungmoo Ryu ,  Stuart Rosenberg ,  Allen Keel ,  Taraneh Ghaffari Farazi ,  Richard Williamson ,  Mark Carlson

    IPC分类号： A61N1/365

    CPC分类号： A61N1/36521 ,  A61N1/3622 ,  A61N1/3684 ,  A61N1/3686 ,  A61N1/3962

    摘要： An implantable medical device includes a lead configured to be located proximate to the left ventricle (LV) of the heart, the lead including multiple LV electrodes to sense cardiac activity at multiple LV sensing sites. The a detection module to detect an arrhythmia that represents at least one of a tachycardia and fibrillation based at least in part on the cardiac activity sensed at the multiple LV sensing sites. The ATP therapy module to identify at least one of an ATP configuration or an ATP therapy site based on the cardiac sensed activity at the LV sensing sites, the ATP therapy module to control delivery of antitachycardia pacing (ATP) therapy at the ATP therapy site. The ATP therapy module delivers a stimulus to electrodes at one or more of an LV site, right ventricular (RV) site and right atrial (RA) site, the detection module to sense evoked responses at the LV sensing sites, the ATP therapy module to designate the ATP therapy site to include at least the LV sensing site with a shortest activation time relative to the one or more LV site, RV site and RA site where the stimulus is delivered.

    摘要翻译： 可植入医疗装置包括被配置为位于心脏左心室（LV）附近的引线，该引线包括多个LV电极以感测多个LV感测部位的心脏活动。 该检测模块至少部分地基于在多个LV感测位点处感测到的心脏活动来检测代表心动过速和颤动中的至少一种的心律失常。 ATP治疗模块基于LV感测位点处的心脏感测活动来鉴定ATP配置或ATP治疗部位中的至少一个，ATP治疗模块用于控制ATP治疗部位的抗心动过速起搏（ATP）治疗的递送。 ATP治疗模块向LV位点，右心室（RV）位点和右心房（RA）位点的一个或多个处的电极施加刺激，检测模块用于感测LV感测位点处的诱发反应，ATP治疗模块 指定ATP治疗部位至少包括相对于传递刺激物的一个或多个LV部位，RV部位和RA部位具有最短激活时间的LV感测部位。